Prediction of IBD Disease Activity in Individual Patients Based on PROMs and Clinical Data

NCT ID: NCT05578768

Last Updated: 2022-10-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-03

Study Completion Date

2025-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed study will use a PROM (Patient report Outcome Measurement)-tool in combination with clinical and biochemical data to train and validate a Relapse Prediction Model for individual patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to train and validate a relapse prediction model for individual patients available for daily (remote) care management. Besides that, risk-based care pathways for different prediction outcomes will be evaluated, prediction scores will be correlated to medication type, CRP/Calprotectin and/or endoscopy, and with known IBD clinical risk profiles. Moreover dietary intake will be correlated with the IBD risk profiles.

Study design: Multicentre, retrospective analysis of two prospective cohorts. Study population: Adult IBD patients. Main study parameters/endpoints: The endpoint will be a prediction regarding step-up or step-down in the care pathways. In other words, the percentage of patients in each individual care pathway with agreement between risk score of the individual patient and actual flares during a follow-up time of 24 months. Furthermore insight will be gained in dietary patterns amongst patients with different IBD risk profiles.

No benefits or risks are associated with participating in this study, because only standard of care is given.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IBD Inflammatory Bone Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

training phase

The study procedures for both cohorts are the same.

No intervention

Intervention Type OTHER

Patients will receive standard of care.

validation phase

The study procedures for both cohorts are the same.

No intervention

Intervention Type OTHER

Patients will receive standard of care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Patients will receive standard of care.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult IBD patients
* Subjects willing and able to sign informed consent
* Own and are able to use a smart phone (Android or iOS)

Exclusion Criteria

* Unwilling or unable to adhere to the protocol
* Unwilling or unable to adhere to the informed consent
* Age \<18y
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alrijne Hospital

OTHER

Sponsor Role collaborator

Maasstad Hospital

OTHER

Sponsor Role collaborator

Leiden University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Andrea E. van der Meulen - de Jong, MD, PhD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

A.E. van der Meulen - de Jong, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Leiden University Medical Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Leiden University Medical Centre

Leiden, South Holland, Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

L.J.M. Koppelman, Msc.

Role: CONTACT

0031715297902

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

L.J.M. Koppelman, MSc

Role: primary

0031715297902

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

nWMODIV2_2022020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TOD-IBD: Empowering Patients On-Demand
NCT06179563 ENROLLING_BY_INVITATION NA
Nutrition and Clinical Outcomes in IBD
NCT06550310 NOT_YET_RECRUITING